- Trial phase
- Approved
- Time to market
- Already on the market since 2012. Generic competition entered in June 2026.
- Why 3/10
- Bosulif is an already-approved, marketed drug with no pending PDUFA date, Advisory Committee, or pivotal readout scheduled in the next 12 months. The defining binary event (generic entry) occurred in June 2026. For Pfizer, a $63B+ revenue company, Bosulif's roughly $600M in annual sales is a small contributor, so even complete erosion would not drive a material share-price move. ImpactScore is 3 per the rubric: approved and commercializing with no pending regulatory decision.
Bosulif has no upcoming FDA decision or pivotal readout. The key event already occurred in June 2026 with the launch of generic bosutinib, which will progressively erode brand revenue. For Pfizer investors, the drug is too small to move the stock meaningfully; the more relevant Pfizer catalysts are its broader pipeline readouts and overall revenue trajectory.
Price Chart
Executive Summary
Bosulif (bosutinib) is Pfizer's approved oral tyrosine kinase inhibitor for Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), first FDA-approved in September 2012. The drug is a mature, marketed product facing a significant loss of exclusivity event: generic competition launched in June 2026, with Dr. Reddy's launching the 400mg strength (with 180-day exclusivity) and Alembic launching 100mg and 500mg generics. Bosulif is a small product within Pfizer's roughly $63B annual revenue base, with estimated global sales around $611M in 2025. There are no upcoming binary catalysts (PDUFA dates, pivotal readouts) for this drug, and the generic erosion story is already in motion.
How It Works
Bosulif is a targeted oral cancer drug that blocks a specific abnormal protein called BCR-ABL, which drives the growth of leukemia cells in chronic myelogenous leukemia (CML). By inhibiting this protein and related Src-family kinases, it slows or stops the proliferation of cancer cells.
Trial Status
Bosulif was FDA-approved in September 2012 for adult patients with Ph+ CML. It is approved for both newly diagnosed chronic-phase CML and previously treated patients (including those with resistance or intolerance to prior therapy). The drug is commercially marketed and has an established safety/efficacy profile from multiple clinical trials.
The Two-Sided Case
Upcoming Catalysts
- No upcoming binary catalysts for Bosulif. The drug is already approved and generic competition has launched.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report